Acrivon Therapeutics, Inc. (ACRV) shares fell 28.71%, trading at $2.1044, down $0.8456, after the company reported updated Phase 2b clinical results for its lead candidate ACR-368 in endometrial cancer.
The sell-off came following publication of interim data showing promising confirmed response rates in patients with the serous subtype of endometrial cancer, including a 52 percent overall confirmed response rate in patients with two or fewer prior lines of therapy and a 67 percent rate in biomarker-positive subjects. Acrivon also said it plans to expand the trial into the European Union to accelerate patient enrollment.
On the day of the release, ACRV opened near $2.95, dropped to an intraday low of around $1.98, and reached a high of nearly $3.12, compared to its previous close of $2.95. The stock trades on the Nasdaq.
Trading volume was well above the stock's average daily level, as investors reacted sharply to the mixed interpretation of clinical outcomes.
Acrivon's 52-week range is approximately $1.05 - $8.00, reflecting volatility tied to clinical trial progress and investor sentiment in the biotech sector.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.